1.89
1.89 (0%)
As of Dec 26, 2024
Acumen Pharmaceuticals, Inc. [ABOS]
Source:
Company Overview
Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer’s disease, or AD. Alzheimer’s disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death.
| Country | United States |
| Headquarters | charlottesville, virginia |
| Phone Number | (434) 297-1000 |
| Industry | manufacturing |
| CEO | Daniel O’Connell |
| Website | clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-114 |
| Net Income | $-102.3 |
| Net Cash | $-31.3 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -37.3% |
| Profit as % of Stockholder Equity | -56.3% |
Management Effectiveness
| Return on Equity | -56.3% |
| Return on Assets | -42.8% |
| Turnover Ratio | |
| EBITA | $-114 |
Balance Sheet and Cash Flow Measures
| Total Assets | $239 |
| Total Liabilities | $57.2 |
| Operating Cash Flow | $-86.2 |
| Investing Cash Flow | $48 |
| Financing Cash Flow | $6.9 |
